Neomycin (sulfate)

• Description :

  Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H317, H334

• Target :

  Antibiotic; Bacterial; Phospholipase

• Type :

  Natural Products

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Neomycin-sulfate.html

• Purity :

  99.86

• Solubility :

  DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 250 mg/mL (ultrasonic)

• Smiles :

  O[C@H]1[C@H](O)[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]3O[C@H](CO)[C@@H](O[C@H]4O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]4N)[C@H]3O)O[C@@H]1CN.[3H2SO4]

• Molecular Formula :

  C23H52N6O25S3

• Molecular Weight :

  908.88

• Precautions :

  H317, H334

• References & Citations :

  [1]Sasseville D. Neomycin. Dermatitis. 2010;21 (1) :3-7.|[2]Hu GF. Neomycin inhibits angiogenin-induced angiogenesis. Proc Natl Acad Sci U S A. 1998;95 (17) :9791-9795.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Natural Products

• Clinical Information :

  Launched

• Isoform :

  Aminoglycoside

• Citation 01 :

  Adv Sci (Weinh) . 2025 Apr;12 (16) :e2415041.|Adv Sci (Weinh) . 2025 Mar 31:e2416348.|Adv Sci (Weinh) . 2025 Oct 13:e09383.|Am J Chin Med. 2024 Aug 21:1-28.|Aquaculture. 2021, 736248.|Biochem Biophys Res Commun. 2025 Jun 7:776:152161.|Biochem Pharmacol. 2024 Dec;230 (Pt 2) :116593.|Brain Behav Immun. 2021 Feb:92:102-114.|Cancer Cell. 2025 Sep 25:S1535-6108 (25) 00394-0.|Cancer Immunol Res. 2022 Dec 2;10 (12) :1542-1558.|Cancer Res. 2025 Jul 2;85 (13) :2468-2484.|Cell Biochem Biophys. 2025 Oct 31.|Cell Death Dis. 2021 Jun 7;12 (6) :582.|Cell Death Discov. 2022 Feb 22;8 (1) :77.|Cell Metab. 2023 Nov 7;35 (11) :1961-1975.e6.|Cell Metab. 2025 Jan 7;37 (1) :87-103.e10.|Cell Rep Med. 2024 Sep 21:101753.|Cell Rep. 2021 Sep 7;36 (10) :109660.|Cell Rep. 2023 Dec 27;43 (1) :113591.|Clin Transl Med. 2024 Oct;14 (10) :e70038.|CNS Neurosci Ther. 2025 Feb;31 (2) :e70253.|EMBO Rep. 2024 Nov;25 (11) :4827-4845.|Emerg Microbes Infect. 2022 Dec;11 (1) :815-828.|Exp Neurol. 2025 Jan 8:385:115142.|Food Funct. 2025 Jul 14;16 (14) :5885-5899.|Front Aging Neurosci. 2022 Jul 28;14:858130.|Gut Microbes. 2023 Dec;15 (2) :2249143.|Gut Microbes. 2023 Dec;15 (2) :2282790.|Gut Microbes. 2024 Jan-Dec;16 (1) :2390164.|Int J Biol Macromol. 2024 Sep 19:135835.|J Cell Physiol. 2022 Mar;237 (3) :1845-1856.|J Nanobiotechnology. 2024 Apr 8;22 (1) :157.|J Nanobiotechnology. 2025 Jun 13;23 (1) :443.|J Pineal Res. 2024 Apr;76 (3) :e12954.|Life Metab. 2025 Oct 8.|Life Sci. 2020 Nov 15;261:118473.|Microbiologyopen. 2019 Oct;8 (10) :e873.|Mol Cell Biochem. 2021 Jun;476 (6) :2503-2512.|Mol Immunol. 2022 Sep:149:94-106.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398 (4) :3681-3695.|Neurotherapeutics. 2023 Sep;20 (5) :1405-1426.|NPJ Biofilms Microbiomes. 2024 Oct 28;10 (1) :111.|Nutrients. 2023 Oct 18;15 (20) :4427.|Pharmacol Res. 2024 May 21:205:107229.|Res Sq. 2024 Oct 02.|Research (Wash D C) . 2024 Jul 16:7:0415.|Sci Adv. 2023 Feb 17;9 (7) :eade4770.|SSRN. 2023 Sep 11.|STAR Protoc. 2025 Jan 23;6 (1) :103585.|Water. 2025 Jun 6.|Adv Sci (Weinh) . 2025 Apr 28:e2409837.|Genome Biol. 2023 Apr 30;24 (1) :98.|iScience. 2025 May 13;28 (7) :112658.|iScience. 2025 May 27;28 (6) :112763.|J Agric Food Chem. 2024 Apr 10.|Neoplasia. 2024 Jan:47:100963.|Neural Regen Res. 2024 Sep 1;19 (9) :2081-2088.

• CAS Number :

  [1405-10-3]